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ASC-US: atypical squamous cells of undetermined significance 
CI: confidence interval (95%) 
CIN: cervical intraepithelial neoplasia 
HC2: hybrid capture 2 
HPV: human papilloma virus 
hrHPV: high-risk human papilloma virus 
HSIL: high-grade squamous intraepithelial lesion 
LBC: liquid-based cytology 
LSIL: low-grade squamous intraepithelial lesion 
NPV: negative predictive value 
NTCC: New Technologies for Cervical Cancer 
PCR: polymerase chain reaction 
PPV: positive predictive value 
RCT: randomized controlled trial 
RLB: reverse line blot 
ROC: receiver operating characteristic 
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Novelty and Impact statement 
The accuracy of cytology, p16 immunostaining and genotyping as triage tests was previously 
assessed but each was considered individually (except cytology with partial genotyping). Here their 
combined use was studied.  Our results show that hrHPV positive women who are negative for p16 
and either cytology (LSIL threshold) or HPV16 have a very low CIN3+  in the following three 
 3 
years, and could be safely recalled after such interval, resulting in a relevant overall reduction of 




HPV testing is very sensitive for primary cervical screening but has low specificity. Triage tests 
which improve specificity but maintain high sensitivity are needed. 
Women enrolled in the experimental arm of phase 2 of the NTCC randomised controlled cervical 
screening trial were tested for high risk human papillomavirus (hrHPV) and referred to colposcopy 
if positive. hrHPV positive women also had HPV genotyping (by PCR with GP5+/GP6+ primers 
and reverse line blotting), immunostaining for p16 overexpression and cytology. We computed 
sensitivity, specificity and positive predictive value (PPV) for different combinations of tests, and 
determined potential hierarchical ordering of triage tests.  
1091 HPV positive women had valid tests for cytology, p16 and genotyping. Ninety two of them 
had CIN2+ histology and 40 CIN3+. The PPV for CIN2+ was >10% in hrHPV positive women 
with HSIL+ (61.3%), LSIL+ (18.3%) and ASC-US+ (14.8%) cytology, p16 positive (16.7%) and, 
hierarchically, for infections by HPV33, 16, 35, 59, 31 and 52 (in decreasing order). Referral of 
women positive for either p16 or LSIL+ cytology had 97.8% sensitivity for CIN2+ and woman 
negative for both of these had a 3-year CIN3+ risk of 0.2%. Similar results were seen for women 
either p16 or HPV16/33 positive. 
hrHPV positive women who were negative for p16 and cytology (LSIL threshold) had a very low 
CIN3+ rate in the following three years. Recalling them after that interval and referring those 
positive for either test to immediate colposcopy seems an efficient triage strategy.  The same applies 







Screening based on HPV testing allows earlier diagnosis of high-grade cervical intraepithelial 
lesions (CIN) than cytology-based screening
 
and is more effective in preventing subsequent 
invasive cervical cancer.
1,2
 However, the specificity of HPV testing for high-grade CIN is lower
3
 
and better methods are needed for selecting which HPV positive women need immediate 
colposcopy. Randomized control trials (RCTs) have shown that referring to colposcopy only those 
HPV positive women who also had abnormal cytology or persistent HPV infection leads to 
increased efficacy vs. cytology-based screening, without increasing the biopsy rate.
2
 However, short 
term repeat tests are needed, which can produce anxiety
4
 and entail appreciable loss to follow–up.
5 
 
Triage protocols which can safely allow longer intervals for low risk women are desirable. For 
women known to be positive for high risk HPV (hrHPV), we previously found p16 over-
expression,
6
 abnormal cytology (ASC-US or higher),
7
 and infection by HPV types 16, 33 or 35
8 
to 
have cross-sectional sensitivities for CIN3+ of 91%, 88% and 67% respectively. Here we consider 
the safety of restricting immediate colposcopy to those hrHPV positive women who are positive for 
one or more of these tests, while returning the remainder to 3-year follow up. 
 
For this purpose, we used material collected in phase 2 of the New Technologies for Cervical 
Cancer screening (NTCC) RCT where all HPV positive women were referred to colposcopy thus 
avoiding verification bias. Given the long interval needed for progression from <CIN3 to invasive 
cancer
9
, CIN3 present at study entry and left untreated is the primary concern for cancer 
development in the next 3 years. However, as some CIN3 present at baseline could have been 




NTCC is a randomized trial conducted within nine population-based cervical screening programmes 
in Italy. Women aged 25-60 years who were not pregnant, had never undergone hysterectomy, had 
not been treated for CIN in the last 5 years, and who were attending for a new routine cervical 
screening appointment were randomly assigned to conventional cytology or to HPV-based 
screening, either in combination with liquid-based cytology (phase 1)
10,11
 or alone (phase 2).
12
 
During phase 2, hrHPV testing was done using Hybrid Capture 2 (HC2; Qiagen, Hilden, Germany) 
on samples of cervical cells collected in Standard Transport Medium (STM; Qiagen). Women were 
referred for colposcopy if the HPV test was positive.
12
 As a rule, women with CIN2+ were treated 
and those <CIN2 followed up colposcopically. If no CIN was detected, hrHPV positive women 
were recalled for annual repeat testing with HC2 and ThinPrep liquid based cytology (LBC) for as 
long as their HPV test remained positive, and referred to colposcopy only if cytology became ASC-
US or higher. Women from both arms who were screen-negative at baseline were invited for a 
second screening round 3 years later using conventional cytology and managed according to the 
standard protocol for each centre. Full details have been reported previously.
1 
 
NTCC is registered as an International Standard Randomised Controlled Trial, number 
ISRCTN81678807. We obtained multicentre and local research ethics approvals. 
 
Genotyping. During phase 2, in all centres except Verona, residual material after a positive HC2 
test was stored as 400μL aliquots in STM at -80°C. Only the first HC2 positive sample from each 
woman was considered in this analysis. Genotyping was performed blind to histology results by 
PCR with GP5+/GP6+ primers, followed by reverse line blot (RLB) genotyping assay.
13 
Analysis of 
HPV genotyping was restricted to the 13 hrHPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 
68) detected by HC2.  
 7 
 
Cytology and p16 immunostaining. In the experimental arm of Phase 2, ThinPrep cytology was 
routinely prepared at first colposcopy. In all study centres except Verona and Viterbo, after 
preparation of one slide for cytology, 2ml of the residual fluid was shipped for centralised 
immunostaining of cytospin slides with the CINtec™ p16-INK4A Cytology kit.
6
 At the time of 
testing, the dual stain including ki-67 was not available. For logistical reasons, sample collection 
started at different times in different centres. In 5 centres a random sample of 20% of specimens 
from women who had no biopsy taken at colposcopy were discarded to reduce costs. Methods have 




A p16-INK4A negative result was defined as no cell staining or staining of just morphologically 
normal endocervical, metaplastic or atrophic cells, or bacteria. The presence of any other p16 
positive cell, including superficial, intermediate and parabasal normal and all abnormal cells, was 
defined as positive. Slides were independently read by two investigators, blind to cytological and 
histological diagnosis, and discordant readings were resolved by consensus review blinded to all 
other data (except HPV positivity). 
 
Endpoint assessment. Endpoints were histologically confirmed CIN3+ and CIN2+, which included 
invasive cervical cancer and adenocarcinoma in situ. At the end of the recruitment phase all 
histological specimens taken within one year of referral to colposcopy and locally diagnosed as 
CIN1 or higher were reviewed by a group of pathologists who were blinded to the original 
diagnosis and randomisation. Centrally reviewed biopsies after any follow up colposcopy within 3.5 
years of entry were also obtained (to allow for a small delay in attendance) and included in a ‘3-
year’ longitudinal analysis. Random biopsies were not taken in women when no abnormal area was 
seen on colposcopy.  
 8 
 
Statistical analysis. The cohort consisted of all hrHPV positive women who had valid tests for 
cytology, p16 immunostaining and genotyping. A ‘baseline’ analysis was based on disease detected 
within 12 months of the first referral to colposcopy. We also considered disease detected within 3.5 
years after the first colposcopy to measure disease up to and including the usual time until the next 
regular screening. This is denoted as “detected within 3 year follow-up” below. Three and a half 
year follow up was complete for 84.3% of HPV+ women without disease (CIN2+) detected at 
baseline.  
 
For the analysis we considered five cytology categories (unsatisfactory, normal, ASC-US, LSIL, 
HSIL+) and two for p16 (positive/negative). Individual genotyping for the 13 hrHPV types positive 
by HC2 using GP5+/6+ primers were also examined. In order to limit overfitting issues, we defined 
a priori a selection procedure where markers had to separately have a positive predictive value 
(PPV) of at least 10% for CIN2+ to be considered in combination. 
 
Sensitivity, specificity, PPV, and false negative reports (1-NPV (negative predictive value)) for 
CIN2+ and CIN3+ were computed for combinations of markers. CIN1 and normal were grouped as 
<CIN2 for all analyses. For individual genotyping a hierarchical ordering of HPV types was 
developed based on sequentially maximizing the PPV for the next HPV type after excluding women 
with multiple infections with types higher in the hierarchy.  
 
Data Availability. According to Italian law, anonymized data can only be made publicly available 
if there is no potential for the re-identification of individuals (https://www.garanteprivacy.it). The 
data underlying this study or ad-hoc analyses are available on request to researchers who meet the 
criteria for access to confidential data. Requests should be addressed to the Corresponding Author. 
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RESULTS 
During phase 2 of NTCC, 1936 (7.9%) women from the experimental arm were positive for hrHPV 
by HC2 and 1813 (93.6%) of these had colposcopy. Details of their follow up are shown in Figure 
1. Within this group, 1547 woman came from centres where samples were collected for cytology, 
p16 and genotyping. Biopsies were taken in 41.8% (647/1547) of women who had colposcopy and 
the remainder were considered negative. Complete test results for cytology, p16 and genotyping 
were available for 1091 hrHPV positive women (Figure 1). Overall, 138 of these women were 
diagnosed with CIN2+ at baseline or during follow up, including 60 with CIN3+, and 4 with 
invasive cervical cancer.  
 
Disease detected at baseline (Cross-sectional analysis) 
 At baseline 92 women were diagnosed with CIN2+ and 40 of these had CIN3+. The sensitivity of 
HSIL+ cytology was only 53.3% (42.6, 63.7) for CIN2+ and 60.0% (43.3, 75.1) for CIN3+, but 
specificity for <CIN2 was very high (96.9% (95.6, 97.9)) (Table 1a). For LSIL+ cytology the 
sensitivity for CIN2+ increased to 73.9% (63.7, 82.5), but specificity was reduced to 69.6% (66.6, 
72.4) (Table 1b), while for ASC-US+ cytology sensitivity increased further to 87.0% (78.3, 93.1) 
but specificity was reduced to 53.8% (50.6, 56.9) (Table 1c).  
 
A total of 468 (42.9%) women were positive for p16 immunostaining. The sensitivity was 84.8% 
(75.8, 91.4) for CIN2+ and 90.0% (76.3, 97.2) for CIN3+, with a specificity for <CIN2 of 61.0% 
(57.9, 64.0) (Table 1b). p16 detected more CIN2+ than LSIL+ (73.9%), HPV16 (54.4%) or 
HPV16/33 (62.0%) (Table 1b). 
 
HPV16 was the commonest genotype detected overall (N=308, 28.2%) and after omitting the 11 
multiple infections with types higher in the hierarchy (i.e. only HPV33, Supplementary Table 1a) it 
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had a similar PPV for CIN2+ as p16 (16.5% vs 16.7%), but slightly lower than LSIL+ cytology 
(18.3%) (Table 1b). Ordering genotypes (with PPV>10%) by decreasing PPV, HPV33 was ranked 
first with a PPV of 20.9% (10.0, 36.0) for CIN2+ (11.6% (3.9, 25.1) for CIN3+), followed by 
HPV16, 35, 59, 31 and 52 (Supplementary Table 1a). However, the number of CIN2+ cases for 
HPV types 35, 59, 31 and 52 was very small. HPV18 had a lower discriminatory value with a PPV 
of only 7.3% (2.4, 16.1). 
 
Combinations of cytology (ASC-US+, LSIL+, HSIL+), p16 positivity and genotyping for HPV 
types 16 and 33 were considered, as each had univariate PPV values for CIN2+ greater than 10% 
(Table 1, Figure 2). Almost all CIN2+ disease was either LSIL+ or p16 positive (sensitivity 97.8% 
(92.4, 99.7) for CIN2+ and 97.5% (86.8, 99.9) for CIN3+), and only referring women positive for at 
least one of these makers reduced referrals by 40.7%, compared to referring all hrHPV positive 
women (Table 1b). Very similar performance was seen if only p16 or HPV16 positive women were 
referred (Table 1b). Lower sensitivity was seen if only those who were HPV16+ or LSIL+ were 
referred (sensitivity 84.8% (75.8, 91.4) for CIN2+ and 87.5% (73.2, 95.8) for CIN3+), and in this 
case 51.7% of women would have been referred to colposcopy. Including ASC-US+ cytology 
increased sensitivity (ASC-US+ and/or HPV16+: 92.4% (85.0, 96.9) for CIN2+ and 92.5% (79.6, 
98.4) for CIN3+), but at the expense of referring another 10.7% of the population (Table 1c). 
Adding HPV33 positivity only slightly improved performance compared to HPV16 alone, or with 
p16 or LSIL+ cytology (Table 1), but the number of cases was too small to draw conclusions. 
Figure 2 shows graphically the cross-sectional added sensitivity and reduced specificity for 
combinations of p16 IHC, genotyping, and LSIL+ cytology. 
 
As only one positive triage test is needed for referral, we looked at the order in which they might be 
applied to avoid unnecessary tests and reduce costs. As discussed below, this will depend on what is 
 11 
routinely available, but ignoring the routine availability of any results and costing details (which 
will depend on local policy), we considered an ordering based on reducing the overall number of 
tests performed. As p16 was most often positive (n=468), the number of tests is minimized by doing 
this first, followed by either cytology (LSIL+) (179 additionally positive) or genotyping (HPV16 
positive) (161 additionally positive), where the choice between them was marginal. With this 
approach a second (reflex) test would have been needed in only 57% of HPV-positive women. 
There was little gain in disease detection in doing all three tests.  
 
Disease detected at follow up (longitudinal) 
A further 46 CIN2+ including 20 CIN3+ cases were diagnosed during follow up (Supplementary 
Table 1b). Of the additional CIN2+ cases, 6 (13.0%) were HSIL+, 22 (47.8%) LSIL+, and 35 
(76.1%) ASC-US+, 30 (65.2%) were p16 positive and 19 (41.3%) HPV16 positive. One case of 
invasive cervical cancer was detected at 13 months during follow up and this case had ASC-US 
cytology and was also positive for HPV16 and p16. She had no biopsy at the first colposcopy and 
did not receive 1 year follow up screening in the organised program. 
 
Including disease detected either at baseline or follow up, only 13/138 cases (9.4%) of CIN2+ and 
4/60 (6.7%) cases of CIN3+ were <LSIL and negative for p16 at entry (Table 2). Only six CIN2+ 
and one CIN3+ of these cases were positive for HPV16. If using p16 or HPV16 positivity for triage, 
15 (10.9%) CIN2+ and 6 (10.0%) CIN3+ would have been false negative (Table 2). The 3-year 
sensitivity for different triage strategies is illustrated in Supplementary Figure 1.  
 
Including baseline and follow up, the PPV for CIN2+ increased to 23.1% (19.3, 27.2) for p16 
positivity (10.9% (8.2, 14.1) for CIN3+), and to 19.3% (16.4, 22.6) for LSIL+ or p16 positivity 
(8.7% (6.6, 11.1) for CIN3+). For p16 and HPV16 positivity, PPVs increased to 19.6% (16.5, 22.9) 
 12 
for CIN2+ and to 8.6% (6.5, 11.1) for CIN3+ (Table 2). Supplementary Table 2a&b show the 
diagnostic accuracy, including baseline and follow up, for ASC-US+ and HSIL+ cytology in 
combination with p16 and genotyping. 
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DISCUSSION 
Testing for hrHPV is well known to be the most sensitive method currently available for primary 
screening. However good triage tests are needed to improve specificity. There are several 
possibilities including cytology, HPV genotyping, p16 immunostaining and DNA methylation, but 




 review data on the use of p16 with or without Ki-67 as triage for abnormal cytology 
and Wright et al.
15
 compare p16/Ki-67 to cytology in HPV positive women in the ATHENA trial. 
In both cases support for p16 immunostaining is provided, but these studies only provided cross-
sectional evaluation, without adequate follow up. Our cross-sectional results are similar to those 
from the PALMS study
16
 and the PaVDaG study,
17
 which showed much greater cross-sectional 
sensitivity for dual stained p16/Ki-67 than pap cytology or HPV16/18 genotyping, but again 
longitudinal follow up and genotyping beyond types 16 and 18 was not performed in either of these 
studies. Clarke et al.
18 
also showed much better detection rates over a 5 year follow up with dual 
p16/Ki-67 staining than for cytology. Wright et al.
15
 have also shown increased sensitivity for 
detection of CIN2+ and CIN3+ for HPV positive women when using p16/Ki-67 and/or HPV16/18 
genotyping as a triage strategy compared to only cytology, but again longitudinal follow up was not 
reported nor was complete HPV genotyping performed. 
 
A very recent cohort study
19
 of women screened by co-testing with HPV and cytology also 
performed a supplementary research dual stain (p16/Ki67) test which was not used for management 
and included a 3-year follow up. They considered the accuracy of cytology at an ASC-US cut-off 
and of genotyping for HPV16/18 (but not full genotyping). In this cohort HPV-positive/cytology-
negative women had no colposcopy if they were HPV negative at re-testing, leaving the possibility 
of some verification bias. However the sensitivity of dual staining was very similar to our findings 
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suggesting that bias was minimal. The authors of this study concluded that extending screening 
intervals to 3 years in HPV16/18 negative women who are dual-stain negative was safe, but did not 
consider combinations of dual staining with cytology. 
 
Our results indicate that HPV positive women who are negative for both p16 immunostaining and 
LSIL+ cytology have a very low risk of CIN2+ (0.5% (0.1, 1.6)) and especially CIN3+ (0.2% (0.01-
1.3)) at an initial colposcopy, and this risk remains low after 3-year follow up (2.9% (1.6, 5.0) and 
0.9% (0.3, 2.3) respectively). No cancer was diagnosed during the 3-year follow up in women 
negative for either of these triage combinations. 
 
The high sensitivity of the triage strategies proposed would allow re-testing triage-negative women 
after 3 years, so avoiding a substantial number of short-term repeat tests, and reducing costs, 
anxiety for women, and loss to follow up. The triage strategies proposed would also avoid a 
substantial number of colposcopies. Immediate referral to colposcopy appears to be slightly higher 
(59.3% of HPV positives when referring either p16 positive or LSIL+ women, 57.7% when 
referring HPV positive women for either p16 or HPV16) compared to the currently widely used 
ASC-US+ cytology only (49.7%). However, it is lower than the current USA recommendation
20,21
 
of referral of either HPV16+ or ASC-US+ women, which, in our study, would have led to an even 
higher 62.4% immediate referral without any gain in sensitivity.  
 
However, only 10-15 % of HPV infections persist for at least 3 years versus about 40% positivity 
after 1 year.
22
 Therefore re-testing triage negative women for HPV after 3 years and referring to 
colposcopy those still HPV positive will strongly reduce the number of delayed colposcopies 
compared to referral for those persistent after 1 year. We estimate our approach would lead to 
colposcopy referral in about 62-63% of HPV positive women overall, versus 80% if all ASC-US+ 
 15 
or HPV16+ women were referred immediately, and the negatives were managed by annual repeat 
HPV testing. If just ASC-US+ women were referred immediately and negatives were retested after 
1 year the referral rate would be 70%. 
 
It must, however, be kept in mind that short-term follow up is needed for women who have a first 
negative colposcopy. The number of tests needed is expected to be proportional to the overall 
colposcopy referral rate, therefore, it will also be reduced with our proposed strategy.  
 
Reducing the overall number of tests is important but this needs to be viewed in light of the routine 
use of cytology, especially when co-testing with both HPV and cytology is practiced. HPV16/18 
genotyping is also automatically provided with some HPV tests. Genotyping also has the advantage 
of being objective and reproducible, which is not the case for low grade cytology. Costs are 
country-specific and a full economic evaluation is needed to define the most cost-effective strategy. 
 
HPV16 is more common than the other oncogenic types, both in high-grade CIN and invasive 
cancers.
23 
Currently most commercially available HPV tests only genotype for HPV16/18. 
However, it has been shown that other hrHPV types, particularly HPV31 and 33 are associated with 
a high rate of high-grade lesions and PPVs leading to greater sensitivity.
8,23,24
 HPV18 and 45 are not 
strongly associated with CIN3+ in the next 3 years, but are the second and third most common 
types in invasive cervical carcinoma, and are specifically associated with glandular intraepithelial 
lesions and adenocarcinoma. Thus, while it may be useful to test for HPV18 (and HPV45), 
management of positive women needs to be different, as disease yield within 3 years is low and 
only persistent infection after 3 years would seem to warrant colposcopy with a more careful 
exploration of the endocervical canal to look for lesions not apparent in routine colposcopy. A more 
 16 
conservative strategy would be to manage these women with short term (e.g. 1 year) repeat testing, 
but this requires further evaluation in other cohorts. 
 
The NTCC trial was a large, population-based study, nested in routine organized screening in a low-
risk population. Over 70% of eligible women were enrolled in the study,1 suggesting that results are 
applicable to routine practice. One of the main strengths of this study was the referral to colposcopy 
(with high participation) of all HPV positive women, and the 3-year follow up of women who did 
not have CIN2+ initially detected at colposcopy. Such a design minimizes the risk of verification 
bias. In almost all cases the histopathologic endpoint was determined by a central review blinded to 
the HPV test, cytology, p16 and genotyping results. In addition, we also searched cancer registries 
and pathology units for lesions detected outside participating programmes.  
 
We obtained specimens for genotyping and cytology results from a large proportion of the HPV 
positive women in the centres included in the study. A proportion of p16 specimens from women 
without biopsy at baseline were randomly discarded to reduce costs, and the remaining missing 
samples were the result of delayed start in sample collection and can reasonably be considered as 
“missing at random”. Samples for cytology and p16 testing were read in the knowledge of HPV 
positivity. This is known to increase both true positive and false positive rates,
7,25
 and can be seen in 
the lower specificity observed here compared to other studies,
15
 but reflects the proposed use and is 
thus an advantage of this study design. A sample of cytology slides (n=852) were also reviewed 
externally, blind to histology
7
, and results for sensitivity were very similar, but specificity was 
higher than for the original review (data not shown). Genotyping and p16 were blind to histology, 
and performed in different laboratories. 
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Dual staining for p16 and Ki-67 is now widely used in order to minimize subjectivity in 
interpretation, but was not available when we performed immunostaining. Results suggest similar 
sensitivity as for stand-alone p16, but better specificity.
26 
However, the sensitivity of p16 could 
have been underestimated due to the use of cytospin preparations instead of full-size standard LBC 
slides. We found that extended genotyping to detect HPV33 improved performance, but the gain 
was small. 
 
In conclusion our data suggest that p16 immunostaining combined with either cytology or some 
level of genotyping should be used to triage HPV positive women. This can maintain high 
sensitivity and lead to a substantial reduction in the number of women referred for colposcopy or 





Disclaimer. The authors alone are responsible for the views expressed in this paper and they do not 
necessarily represent the views, decisions or policies of the institutions with which they are 
affiliated. 
Contributors. GR was the PI of NTCC. GR and JC conceived and designed the present study. AG-
T, LDM, ADM, HF, FC, CS and SG organised and conducted the local collection and storage of 
biological samples and genotyping. FC and MC organised p16 immunostaining and interpreted 
slides. RR, PGR and MZ organized the fieldwork and follow-up and contributed to data 
interpretation. RR and RA did the statistical analysis under the supervision of JC and GR. JC, GR, 
RA and RR drafted the manuscript. All authors critically reviewed the manuscript. 
Acknowledgments. This study was supported by the Italian Ministry of Health (Progetto Speciale 
“Valutazione di nuove tecnologie per lo screening del cervicocarcinoma – follow-up” and l 138–
2004 progetto “NTCC—nuove tecnologie per lo screening del cervicocarcinoma”), by the European 
Union (COHEAHR project, FP7 grant agreement no. Health-F3–2013–603019) and by the 
Associazione Italiana per la Ricerca sul Cancro (AIRC, project IG14119).  
Conflicts of interest.  PGR as former PI of an independent study funded by the Italian ministry of 
health conducted negotiations with Roche, Hologic, Becton Dickinson, Abbott, Qiagen to obtain 
reagents at reduced price or for free. JC is part of the advisory board for Qiagen and FC is part of 
the advisory board of Becton Dickinson. AGT and LDM as molecular lab coordinators, in an 
independent study funded by the Italian Ministry of Health, are conducting negotiations with 
Becton Dickinson to obtain reagents for free and a scholarship holder to perform virus genotyping. 
All other authors reported no conflict of interest. 
Role of the funding source Sponsors had no role in study design, data collection, data analysis, 
data interpretation, or writing of the report. All authors had full access to all the data in the study.  
 19 
REFERENCES 
1. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, 
Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, Rizzolo R, 
Schincaglia P, Zorzi M, Zappa M, Segnan N, Cuzick J; New Technologies 
for Cervical Cancer screening (NTCC) Working Group. Efficacy of human papillomavirus 
testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a 
randomised controlled trial. Lancet Oncol. 2010; 11: 249–57. 
2. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, 
Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, Rizzolo R, 
Schincaglia P, Zorzi M, Zappa M, Segnan N, Cuzick J; New Technologies 
for Cervical Cancer screening (NTCC) Working Group. Efficacy of HPV-based screening 
for prevention of invasive cervical cancer: follow-up of four European randomised 
controlled trials. Lancet. 2014; 383: 524–32. 
3. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, 
Sankaranarayanan R, Peto J. Evidence regarding human papillomavirus testing in secondary 
prevention of cervical cancer. Vaccine. 2012; 30: 88–99. 
4. Waller J, McCaffery K, Kitchener H, Nazroo J, Wardle J. Women's experiences of repeated 
HPV testing in the context of cervical cancer screening: a qualitative study. 
Psychooncology. 2007; 16: 196–204. 
5. Ronco G, Franceschi S, Segnan N. HPV16 and HPV18 genotyping in cervical cancer 
screening. The Lancet Oncology. 2011; 12: 831–2. 
6. Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, De Marco L, Giorgi-
Rossi P, Pontenani G, Rosso S, Sani C, Sintoni C, Segnan N, Zorzi M, Cuzick J, Rizzolo R, 
Ronco G; New Technologies for Cervival Cancer Screening (NTCC) Working Group. Use 
of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a 
nested substudy of the NTCC randomised controlled trial. The Lancet Oncology. 2008; 9: 
937–45. 
7. Bergeron C, Giorgi-Rossi P, Cas F, Schiboni ML, Ghiringhello B, Dalla Palma P, Minucci 
D, Rosso S, Zorzi M, Naldoni C, Segnan N, Confortini M, Ronco G. Informed cytology for 
triaging HPV-positive women: substudy nested in the NTCC randomized controlled trial. J 
Natl Cancer Inst. 2015; 107: dju423. 
8. Del Mistro A, Adcock R, Carozzi F, Gillio-Tos A, De Marco L, Girlando S, Rizzolo R, 
Frayle H, Trevisan M, Sani C, Burroni E, Giorgi Rossi P, Cuzick J, Ronco G; New 
Technologies for Cervical CancerWorking Group. Human papilloma virus genotyping for 
the cross-sectional and longitudinal probability of developing cervical intraepithelial 
neoplasia grade 2 or more. Int J Cancer. 2018; 143: 333–42. 
9. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, Skegg DC. Natural 
history of cervical neoplasia and risk of invasive cancer in women with cervical 
intraepithelial neoplasia 3: a retrospective cohort study. The Lancet Oncology. 2008; 9: 
425–34. 
 20 
10. Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, Dalla Palma P, Del 
Mistro A, Folicaldi S, Gillio-Tos A, Nardo G, Naldoni C, Schincaglia P, Zorzi M, 
Confortini M, Cuzick J; New Technologies for Cervical Cancer Working Group. Human 
Papillomavirus Testing and Liquid-Based Cytology: Results at Recruitment From the New 
Technologies for Cervical Cancer Randomized Controlled Trial. J Natl Cancer Inst. 2006; 
98: 765–74. 
11. Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L, De Lillo M, 
Naldoni C, Pierotti P, Rizzolo R, Segnan N, Schincaglia P, Zorzi M, Confortini M, Cuzick 
J; New Technologies for Cervical Cancer screening Working Group. Human papillomavirus 
testing and liquid-based cytology in primary screening of women younger than 35 years: 
results at recruitment for a randomised controlled trial. The Lancet Oncology. 2006; 7: 547–
55. 
12. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos 
A, Minucci D, Naldoni C, Rizzolo R, Schincaglia P, Volante R, Zappa M, Zorzi M, Cuzick 
J, Segnan N; New Technologies for Cervical Cancer Screening Working Group. Results at 
Recruitment From a Randomized Controlled Trial Comparing Human Papillomavirus 
Testing Alone With Conventional Cytology as the Primary Cervical Cancer Screening Test. 
J Natl Cancer Inst. 2008; 100: 492–501. 
13. van den Brule AJC, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJLM, Snijders PJF. 
GP5+/6+ PCR followed by Reverse Line Blot Analysis Enables Rapid and High-
Throughput Identification of Human Papillomavirus Genotypes. J Clin Microbiol. 2002; 40: 
779–87. 
14. Peeters E, Wentzensen N, Bergeron C, Arbyn M. Meta-analysis of the accuracy of p16 or 
p16/Ki-67 immunocytochemistry versus HPV testing for the detection of CIN2+/CIN3+ in 
triage of women with minor abnormal cytology. Cancer Cytopathol. 2019; 127: 169–80. 
15. Wright TC Jr, Behrens CM, Ranger-Moore J, Rehm S, Sharma A, Stoler MH, Ridder R. 
Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-
study nested into the ATHENA trial. Gynecol Oncol. 2017; 144: 51–6. 
16. Ikenberg H, Bergeron C, Schmidt D, Griesser H, Alameda F, Angeloni C, Bogers J, Dachez 
R, Denton K, Hariri J, Keller T, von Knebel Doeberitz M, Neumann HH, Puig-Tintore LM, 
Sideri M, Rehm S, Ridder R; PALMS Study Group. Screening for Cervical Cancer 
Precursors With p16/Ki-67 Dual-Stained Cytology: Results of the PALMS Study. J Natl 
Cancer Inst. 2013; 105: 1550–7 
17. Stanczuk GA, Baxter GJ, Currie H, Forson W, Lawrence JR, Cuschieri K, Wilson A, 
Patterson L, Govan L, Black J, Palmer T, Arbyn M. Defining Optimal Triage Strategies for 
hrHPV Screen-Positive Women-An Evaluation of HPV 16/18 Genotyping, Cytology, and 
p16/Ki-67 Cytoimmunochemistry. Cancer Epidemiol Biomarkers Prev. 2017; 26: 1629–35. 
18. Clarke MA, Cheung LC, Castle PE, Schiffman M, Tokugawa D, Poitras N, Lorey T, Kinney 
W, Wentzensen N. Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain 
Triage of HPV-Positive Women. JAMA Oncology. 2019; 5: 181–6. 
19. Wentzensen N, Clarke MA, Bremer R, Poitras N, Tokugawa D, Goldhoff PE, Castle PE, 
Schiffman M, Kingery JD, Grewal KK, Locke A, Kinney W, Lorey TS. Clinical Evaluation 
 21 
of Human Papillomavirus Screening With p16/Ki-67 Dual Stain Triage in a Large 
Organized Cervical Cancer Screening Program. JAMA Internal Medicine. 2019; 179: 881–
8. 
20. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FA, 
Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs LS Jr, Spitzer M, Moscicki 
AB, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER. American Cancer Society, 
American Society for Colposcopy and Cervical Pathology, and American Society for 
Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical 
Cancer. Am J Clin Pathol. 2012; 137: 516–42. 
21. Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, Kinney WK, Massad 
LS, Mayeaux EJ, Saslow D, Schiffman M, Wentzensen N, Lawson HW, Einstein MH. Use 
of primary high-risk human papillomavirus testing for cervical cancer screening: interim 
clinical guidance. Obstet Gynecol. 2015; 125: 330–7. 
22. Rositch AF, Koshiol J, Hudgens MG, Razzaghi H, Backes DM, Pimenta JM, Franco EL, 
Poole C, Smith JS. Patterns of persistent genital human papillomavirus infection among 
women worldwide: a literature review and meta-analysis. Int J Cancer. 2013; 133: 1271–85. 
23. Cuzick J, Wheeler C. Need for expanded HPV genotyping for cervical screening. 
Papillomavirus Research. 2016; 2: 112–5. 
24. Cuzick J, Ho L, Terry G, Kleeman M, Giddings M, Austin J, Cadman L, Ashdown-Barr L, 
Costa MJ, Szarewski A. Individual detection of 14 high risk human papilloma virus 
genotypes by the PapType test for the prediction of high grade cervical lesions. J Clin Virol. 
2014; 60: 44–9 
25. Wright TC, Jr., Stoler MH, Aslam S, Behrens CM. Knowledge of Patients’ Human 
Papillomavirus Status at the Time of Cytologic Review Significantly Affects the 
Performance of Cervical Cytology in the ATHENA Study. Am J Clin Pathol. 2016; 146: 
391-8. 
26. Bergeron C, Giorgi-Rossi P, Cas F, Schiboni ML, Ghiringhello B, Dalla Palma P, Minucci 
D, Rosso S, Zorzi M, Naldoni C, Segnan N, Confortini M, Ronco G. Informed cytology for 
triaging HPV-positive women: substudy nested in the NTCC randomized controlled trial. J 


















Table 1. Accuracy for detection of CIN2+ and CIN3+ detected at baseline* 
 
1a. Combinations of HSIL+ cytology, p16 immunostaining, and HPV genotypes for HPV positive woman. (n=1091) 
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HPV16+ 


































 (41.04, 47.29) 
PPV 
61.25 
 (49.70, 71.94) 
17.30 
 (14.00, 21.01) 
19.01 




 (11.05, 16.56) 
13.62 




























































1b. Combinations of LSIL+ cytology, p16 immunostaining, and HPV genotypes for HPV positive woman. (n=1091) 
 
LSIL+ HPV16+ HPV16/33+ p16+ LSIL+ or p16+ 
LSIL+ or 
HPV16+ 
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ASC-US+ or  
HPV16/33+ 
ASC-US+ or p16+ 
or HPV16+ 









































































































*includes lesions detected within 12 months of the first referral to colposcopy
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Table 2. Accuracy for detection of CIN2+ and CIN3+ by combinations of LSIL+ cytology, p16 immunostaining, and HPV genotypes for HPV positive woman. 
Includes all disease detected at baseline and follow-up. (n=1091) 
 
 
LSIL+ HPV16+ HPV16/33+ p16+ LSIL+ or p16+ 
LSIL+ or 
HPV16+ 




LSIL+ or p16+ 
 or HPV16+ 































































































(n = 60) 



























































 (0.48, 2.81) 
0.91  
(0.19, 2.63) 
0.63  
(0.08, 2.24) 
 
 
 
